Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
🎯 Clinical Bottom Line
MA.17R demonstrated that extending aromatase inhibitor therapy with letrozole for an additional five years — after approximately five years of tamoxifen and five years of an AI — significantly reduced breast cancer recurrence and contralateral breast cancer in postmenopausal women with HR+ early breast cancer. There was no overall survival benefit. The decision to extend therapy must weigh recurrence reduction against significantly increased fracture and osteoporosis rates.
Key Result: 5-year DFS — 95% (letrozole) vs 91% (placebo), HR 0.66 (95% CI 0.48–0.91; P=0.01)
Safety Signal: Significantly increased bone fractures (14% vs 9%; P=0.001) and new-onset osteoporosis (11% vs 6%; P<0.001)
✅ Patient Eligibility
Must Have:
- HR+ primary breast cancer
- Postmenopausal
- Disease-free after completing 4.5–6 years of any aromatase inhibitor
- ECOG PS <3
- Minimum 5-year life expectancy
Cannot Have:
- Active breast cancer recurrence
- No age-based exclusion permitted
💊 Dosing Quick Guide
Experimental Regimen
Letrozole: 2.5 mg orally once daily Duration: 5 years
Control Regimen
Placebo: orally once daily for 5 years
Key Dose Modifications [2]
Per FDA prescribing information — not trial protocol - No dose reductions; single fixed dose (2.5 mg) - No specific premedication required - Monitor bone density before and during therapy; manage osteoporosis per guidelines
⚠️ Safety Snapshot
Grade ≥3 adverse event data were not reported separately in this publication. Key any-grade adverse events (during receipt of trial regimen):
| Any-Grade Adverse Event | Letrozole (n=959) | Placebo (n=954) |
|---|---|---|
| Arthralgia | 513 (53%) | 475 (50%) |
| Hot flashes | 360 (38%) | 354 (37%) |
| Arthritis | 317 (33%) | 288 (30%) |
| Bone fracture | 133 (14%) | 88 (9%) |
| New-onset osteoporosis | 109 (11%) | 54 (6%) |
| Cardiovascular event | 116 (12%) | 98 (10%) |
⚠️ Bone fracture: Any grade 14% vs 9% (P=0.001) ⚠️ New-onset osteoporosis: 11% vs 6% (P<0.001); T-score <−2.5: 10% vs 7% (P=0.03)
Key safety metrics:
- Discontinuations due to AE: 5.4% vs 3.7%
- Total deaths: 100 vs 100 (no survival difference)
- Adherence: 62.5% vs 62.3%
📊 Key Numbers
Median follow-up: 75 months (6.3 years)
| Outcome | Letrozole | Placebo | HR (95% CI) | p-value |
|---|---|---|---|---|
| 5-yr DFS (primary) | 95% | 91% | 0.66 (0.48–0.91) | P=0.01 |
| 5-yr OS | 93% | 94% | 0.97 (0.73–1.28) | P=0.83 |
| Contralateral BC (annual rate) | 0.21% | 0.49% | 0.42 (0.22–0.81) | P=0.007 |
| DFS incl. all deaths (post hoc) | 90% | 88% | 0.80 (0.63–1.01) | P=0.06 |
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| MA.17R | Letrozole × 5 yr after ~5 yr AI (+ prior tamoxifen) vs placebo | HR+ early BC, extended adjuvant | 5-yr DFS | HR 0.66; P=0.01 | [1] |
| MA.17 | Letrozole × 5 yr after 5 yr tamoxifen vs placebo | HR+ early BC, extended adjuvant | DFS | see [4] | [4] |
| NSABP B-42 | Letrozole × 5 yr after 5 yr AI vs placebo | HR+ early BC, extended adjuvant | DFS | see [5] | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
The superior effect of letrozole on DFS was observed across all prespecified subgroups (defined by lymph-node status, prior chemotherapy, interval between last AI dose and randomization, and duration of prior tamoxifen). No significant interactions were observed. Individual subgroup HRs were reported in the supplementary appendix only and were not available for extraction.
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Letrozole approved for adjuvant and extended adjuvant HR+ early breast cancer [2] |
| EMA | Approved for adjuvant and extended adjuvant HR+ early breast cancer |
⚠️ Verify current regulatory status before prescribing.
NCCN: Extended AI therapy (up to 10 total years) is an option for postmenopausal HR+ early breast cancer, individualized by recurrence risk and tolerability [3]
⚡ Grey Zones
- No overall survival benefit despite significant DFS improvement — benefit limited to reducing recurrences, not deaths
- Non-standard DFS definition censored deaths without recurrence, inflating DFS rates vs trials using STEEP criteria
- No biomarker-guided selection (e.g., BCI) to identify patients who benefit most from extended therapy
- Adherence was only ~62% in both arms — the tolerability burden of 15 total years of endocrine therapy is substantial
- Long-term cumulative skeletal and cardiovascular effects of ~15 years of total endocrine therapy are unknown
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209-219. doi:10.1056/NEJMoa1604700
- Letrozole (Femara) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2026. Accessed March 2026.
- Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802.
- Mamounas EP, Bandos H, Lembersky BC, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:88-99.